Search results for "ARTERIAL HYPERTENSION"

showing 10 items of 69 documents

Potential of the EPA/DHA 6/1 formulation to prevent endothelial dysfunction and cardiopulmonary remodeling in pulmonary arterial hypertension in rats

2016

Pulmonary arterial hypertension (PAH) is characterized by remodeling of the small pulmonary arteries leading to a progressive increase in pulmonary vascular resistance and right ventricular failure. Pulmonary endothelial dysfunction, inflammation and oxidative stress promote the development of pulmonary hypertension. Omega-3 polyunsaturated fatty acids such as eicosapentaenoic acid (EPA) and docosahexaenoic acids (DHA) have been shown to protect the cardiovascular system and reduce inflammation and oxidative stress. The present study evaluate the potential of EPA:DHA 6:1 to prevent monocrotaline-induced PAH in rats. EPA:DHA 6:1 treatment (500 mg/kg/d, p.o) prevented the MCT-induced mean pul…

MonocrotalineAcide eicosapentaénoîque (EPA)Dysfonction endothélialeInflammation and oxidative stress[CHIM.THER] Chemical Sciences/Medicinal ChemistryDocosahexaenoic acids (DHA)Hypertension artérielle pulmonaireRemodelage pulmonairePulmonary arterial hypertensionAcide docosahexaénoïque (DHA)Remodelage du ventricule droitInflammation et stress oxydant[SDV.SP.PHARMA] Life Sciences [q-bio]/Pharmaceutical sciences/PharmacologyCardiopulmonary remodelinglipids (amino acids peptides and proteins)Pulmonary endothelial dysfunctionEicosapentaenoic acid (EPA)
researchProduct

Relationship between plasma endothelin-1 and aortic stiffness in hypertensive patients with chronic kidney disease

2012

Plasma endothelin aortic stiffnes chronic kidney disease arterial hypertension
researchProduct

Recommendations for the management of patients with obstructive sleep apnoea and hypertension.

2013

This article is aimed at addressing the current state-of-the-art in epidemiology, pathophysiology, diagnostic procedures and treatment options for appropriate management of obstructive sleep apnoea (OSA) in cardiovascular (in particular hypertensive) patients, as well as for the management of cardiovascular diseases (in particular arterial hypertension) in OSA patients. The present document is the result of work performed by a panel of experts participating in the European Union COST (Cooperation in Scientific and Technological research) Action B26 on OSA, with the endorsement of the European Respiratory Society and the European Society of Hypertension. In particular, these recommendations …

Pulmonary and Respiratory MedicineAdultMalemedicine.medical_specialtySleep apnoea COSTMEDLINEArterial hypertension continuous positive airway pressure treatment guidelines hypertension treatment obstructive sleep apnoeaCardiologyMyocardial IschemiaBlood PressureSettore MED/10 - Malattie Dell'Apparato Respiratoriota3111Renin-Angiotensin SystemRisk FactorsEpidemiologymedicinemedia_common.cataloged_instanceHumansIn patientObesityEuropean unionIntensive care medicineStrokeLife StyleSocieties Medicalmedia_commonAgedta3126InflammationSleep Apnea Obstructivebusiness.industryRespirationSleep apneaMED/11 - MALATTIE DELL'APPARATO CARDIOVASCOLAREMiddle Agedmedicine.diseaseObesityEuropeStrokeBlood pressureHypertensionFemaleEndothelium VascularbusinessThe European respiratory journal
researchProduct

Decrease in blood pressure during continuous positive airway pressure treatment for obstructive sleep apnoea: still searching for predictive factors

2019

High blood pressure (BP) and non-dipping 24-hour BP profile may help to predict BP decrease after obstructive sleep apnoea treatment by CPAP. However, specific, highly reproducible traits associated with BP responsiveness to CPAP must still be identified.http://bit.ly/2LbS4uV

Pulmonary and Respiratory Medicinearterial hypertensionmedicine.medical_specialtymedicine.medical_treatmentBlood PressureSettore MED/10 - Malattie Dell'Apparato Respiratorioblood pressure dipping03 medical and health sciences0302 clinical medicineText miningCPAPInternal medicinemedicineHumans030212 general & internal medicineContinuous positive airway pressureobstructive sleep apneatherapySleep Apnea ObstructiveContinuous Positive Airway Pressurebusiness.industryBlood Pressure DeterminationSleep in non-human animalsnervous system diseasesrespiratory tract diseasesBlood pressure030228 respiratory systemHypertensionCardiologybusinessHuman
researchProduct

Mild obstructive sleep apnea increases hypertension risk, challenging traditional severity classification

2020

STUDY OBJECTIVES: The association of mild obstructive sleep apnea (OSA) with important clinical outcomes remains unclear. We aimed to investigate the association between mild OSA and systemic arterial hypertension (SAH) in the European Sleep Apnea Database cohort. METHODS: In a multicenter sample of 4,732 participants, we analyzed the risk of mild OSA (subclassified into 2 groups: mild(AHI 5-<11/h) (apnea-hypopnea index [AHI], 5 to <11 events/h) and mild(AHI 11-<15/h) (AHI, ≥11 to <15 events/h) compared with nonapneic snorers for prevalent SAH after adjustment for relevant confounding factors including sex, age, smoking, obesity, daytime sleepiness, dyslipidemia, chronic obstructive pulmona…

Pulmonary and Respiratory Medicinemedicine.medical_specialtyEuropean Sleep Apnea Database Mild obstructive sleep apnea Systemic arterial hypertensionPolysomnographyDisorders of Excessive SomnolenceSettore MED/10 - Malattie Dell'Apparato RespiratorioHypertension risk03 medical and health sciences0302 clinical medicinestomatognathic systemRisk FactorsInternal medicinesystemic arterial hypertensionmedicineHumansEuropean Sleep Apnea DatabaseSleep Apnea ObstructiveSystemic arterial hypertensionbusiness.industrymedicine.diseaseScientific InvestigationsClinical neurologyrespiratory tract diseasesnervous system diseasesObstructive sleep apneamild obstructive sleep apneaDiabetes Mellitus Type 2NeurologyHypertensionNeurology (clinical)Human medicinebusiness030217 neurology & neurosurgery
researchProduct

Riociguat treatment in patients with pulmonary arterial hypertension: Final safety data from the EXPERT registry

2021

OBJECTIVE: The soluble guanylate cyclase stimulator riociguat is approved for the treatment of adult patients with pulmonary arterial hypertension (PAH) and inoperable or persistent/recurrent chronic thromboembolic pulmonary hypertension following Phase 3 randomized trials. The EXPosurE Registry RiociguaT in patients with pulmonary hypertension (EXPERT) study was designed to monitor the long-term safety of riociguat in clinical practice. METHODS: EXPERT was an international, multicenter, prospective, uncontrolled, non-interventional cohort study of patients treated with riociguat. Patients were followed for at least 1 year and up to 4 years from enrollment or until 30 days after stopping ri…

Pulmonary and Respiratory Medicinemedicine.medical_specialtyRegistryMedDRAPeripheral edemaClinical practicePulmonary arterial hypertensionRiociguatlaw.inventionPulmonary hypertension03 medical and health sciences0302 clinical medicineRandomized controlled triallawInternal medicinemedicine030212 general & internal medicineAdverse effectHipertensió pulmonarRiociguatbusiness.industrymedicine.diseasePulmonary hypertensionClinical trial030228 respiratory systemPulmonary hemorrhagemedicine.symptomSafetybusinessmedicine.drug
researchProduct

ASSOCIATION OF RENAL RESISTIVE INDEX WITH CAROTID INTIMA-MEDIA THICKNESS IN HYPERTENSIVE PATIENTS

2014

RENAL RESISITVE INDEX AORTIC STIFFNESS PULSE WAVE VELOCITY RENAL FUNCTION ARTERIAL HYPERTENSION
researchProduct

Left ventricular hypertrophy or storage disease? the incremental value of speckle tracking strain bull's-eye

2017

Left ventricular hypertrophy (LVH) develops in response to a variety of physical, genetic, and biochemical stimuli and represents the early stage of ventricular remodeling. In patients with LVH, subclinical left ventricular (LV) dysfunction despite normal ejection fraction (EF) may be present before the onset of symptoms, which portends a dismal prognosis. Strain measurement with two-dimensional speckle tracking echocardiography (STE) represents a highly reproducible and accurate alternative to LVEF determination. The present review focuses on current available evidence that supports the incremental value of STE in the diagnostic and prognostic workup of LVH. When assessing the components o…

Radiology Nuclear Medicine and ImagingSpeckle tracking echocardiographyDisease030204 cardiovascular system & hematologyLeft ventricular hypertrophytwo-dimensional strain0302 clinical medicineCardiomegaly Exercise-Induced030212 general & internal medicineanabolic steroidSubclinical infectionamyloidosiEvidence-Based MedicineEjection fractionHypertrophic cardiomyopathyleft ventricular hypertrophyEchocardiographyCardiologyElasticity Imaging TechniquesHypertrophy Left VentricularRadiologyCardiomyopathiesCardiology and Cardiovascular MedicineHumanendocrine systemmedicine.medical_specialtyarterial hypertensionReproducibility of ResultSensitivity and SpecificityDiagnosis Differential03 medical and health sciencesElasticity Imaging TechniqueInternal medicinemedicineathlete's heartHumanscardiovascular diseasesVentricular remodelingspeckle tracking echocardiographyCardiomyopathiebusiness.industryReproducibility of ResultsStroke Volumeaortic stenosiImage Enhancementmedicine.diseasehypertrophic cardiomyopathyDifferential diagnosisMetabolism Inborn ErrorbusinessMetabolism Inborn Errors
researchProduct

Pulmonary hypertension in pediatrics. a feasible approach to bridge the gap between real world and guidelines

2019

Pulmonary hypertension (PH) is quite infrequent in pediatric age and its most common etiologies include idiopathic pulmonary arterial hypertension, PH related to congenital heart diseases, bronchopulmonary dysplasia (chronic lung disease), persistence of pulmonary hypertension of the newborn, and congenital diaphragmatic hernia. The developed for adult patients PH classification shows limitations when applied to pediatric subjects since the underlying causes are markedly different between the two ages. In 2011, the Pulmonary Vascular Research Institute Panama Task Force outlined the first specific pediatric pulmonary hypertensive vascular disease diagnostic classification, including 10 main…

Right heart catheterizationAdultHeart Defects CongenitalPediatricsmedicine.medical_specialtynewbornsHypertension Pulmonary030204 cardiovascular system & hematologyBridge (interpersonal)Pediatrics03 medical and health sciences0302 clinical medicinechildrenpulmonary arterial hypertensionpulmonary hypertensionmedicineHumansright heart catheterizationChildBronchopulmonary Dysplasiabusiness.industrychildren; congenital heart disease; newborns; pulmonary arterial hypertension; pulmonary hypertension; right heart catheterizationIdiopathic Pulmonary Arterial HypertensionInfant NewbornObstetrics and GynecologyPediatric agemedicine.diseasePulmonary hypertensioncongenital heart disease030228 respiratory systemPediatrics Perinatology and Child HealthEtiologybusinessHernias Diaphragmatic Congenital
researchProduct

ASSOCIATION OF SERUM URIC ACID WITH AORTIC STIFFNESS IN UNTREATED HYPERTENSIVE SUBJECTS.

2013

INTRODUCTION: Recent studies have reported an association between serum uric acid (SUA) and reduced arterial elasticity. However, in these studies arterial elastic properties have been assessed chiefly by measuring brachial-ankle pulse wave velocity (PWV) or peripheral PWV and only sometimes by using aortic PWV, that is considered the gold standard for measuring arterial stiffness. Moreover, the studies exploring the influence of SUA on aortic distensibility in subjects with arterial hypertension yielded conflicting results. AIM: The purpose of our study was to evaluate the relationships between SUA and aortic stiffness in a group of essential hypertensive patients. METHODS: We enrolled 222…

SERUM URIC ACIDAORTIC STIFFNESSARTERIAL HYPERTENSION
researchProduct